CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 114 enrolled
Drug / intervention
LumenEye X1 digital rectoscopedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05043363
NCT05043363N/ACompleted

LumenEye During CovID-19 (LuCID Study)

Imperial College London·observational·Posted Sep 14, 2021·Updated Sep 19, 2024

In Brief

An observational study evaluating LumenEye X1 digital rectoscope for Bowel Cancer and 2 related conditions. Completed, enrolled 114 participants across 1 site.

Detailed Summary

The LumenEye scope and CHiP platform will be piloted in a number of clinical settings including remote colorectal clinics. The rationale is to perform an initial pilot study to determine the clinical utility of the LumenEye device for use in primary and secondary care settings. The main hypothesis is that digital rectoscopy is safe and acceptable to clinicians including general practitioners and can significantly reduce the burden of endoscopy referral to and within secondary care centres.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedSep 14, 2021
Enrollment StartNov 14, 2020
Primary CompletionJun 5, 2021
Study CompletionSep 1, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 4.8 years ago

Interventions

LumenEye X1 digital rectoscopedevice

The LumenEye X1 is a novel digital rectoscope that introduces digital HD imaging and improved ergonomics to conventional rigid sigmoidoscopy.